In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 6.3 a new company low.

Within Major Pharmaceutical Preparations industry 179 other companies have achieved higher Quick Ratio than Cybin Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 143 to 605.

Explain Quick Ratio?
How much Cash & cash equivalents CYBN�s has?
What are CYBN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CYBN Quick Ratio	(Mar 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Mar 31 2024) Q4
Y / Y Current Liabilities Change	112.14 %	84.7 %	112.14 %	112.14 %	84.7 %
Y / Y Cash & cash equivalent Change	-35.39 %	1201.74 %	-35.39 %	-35.39 %	1201.74 %
Quick Ratio MRQ	6.3	20.7	6.3	6.3	20.7
CYBN's Total Ranking	# 605	# 143	#	#	#
Seq. Current Liabilities Change	112.14 %	-52.86 %	0 %	112.14 %	84.7 %
Seq. Cash & cash equivalent Change	-35.39 %	54.78 %	0 %	-35.39 %	1201.74 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 180
Healthcare Sector	# 278
Overall Market	# 605

Quick Ratio Statistics
High	Average	Low
20.7	13.5	6.3
(Mar 31 2024)		(Mar 31 2025)

Financial Statements
Cybin Inc 's Current Liabilities	$ 16 Millions	Visit CYBN's Balance sheet
Cybin Inc 's Cash & cash equivalent	$ 103 Millions	Visit CYBN's Balance sheet
Source of CYBN's Sales		Visit CYBN's Sales by Geography

Cumulative Cybin Inc 's Quick Ratio

CYBN's Quick Ratio for the trailling 12 Months

CYBN Quick Ratio	(Mar 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	107.95 %	102.5 %	72.12 %	62.77 %	89.92 %
Y / Y Cash & cash equivalent TTM Growth	-4.51 %	52.86 %	1.01 %	63.69 %	363.79 %
Quick Ratio TTM	8.26	10.92	8.48	12.09	17.98
Total Ranking TTM	# 2485	# 2604	#	#	#
Seq. Current Liabilities TTM Growth	17.96 %	7.93 %	24.05 %	31.67 %	14.88 %
Seq. Cash & cash equivalent TTM Growth	-10.75 %	38.97 %	-13 %	-11.5 %	42.87 %

Quick ratio ranking by company, industry and sector >> Back to CYBN Financial Strength Comparisons >> Go to Compare CYBN Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2025 to $16.41 millions, cumulative Quick Ratio decreased to 8.26 below the Cybin Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 411 other companies have achieved higher Quick Ratio than Cybin Inc . While Quick Ratio overall ranking has improved so far to 2485, from total ranking during the twelve months ending third quarter 2025 at 2604.

Explain Quick Ratio?
How much Cash & cash equivalents CYBN�s has?
What are CYBN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 412
Healthcare Sector	# 807
Within the Market	# 2485

trailing twelve months Quick Ratio Statistics
High	Average	Low
20.7	20.7	20.7
(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Xenon Pharmaceuticals Inc	17.16	$ 549.629 Millions	$ 32.030 Millions
Medicinova Inc	17.14	$ 36.571 Millions	$ 2.134 Millions
Astria Therapeutics Inc	16.93	$ 295.064 Millions	$ 17.426 Millions
89bio Inc	16.86	$ 638.780 Millions	$ 37.884 Millions
Synlogic Inc	16.83	$ 17.271 Millions	$ 1.026 Millions
Lite Strategy Inc	16.54	$ 20.472 Millions	$ 1.238 Millions
Pmv Pharmaceuticals Inc	16.43	$ 160.388 Millions	$ 9.759 Millions
Protagonist Therapeutics inc	16.36	$ 574.360 Millions	$ 35.112 Millions
Connect Biopharma Holdings Limited	16.34	$ 47.712 Millions	$ 2.920 Millions
Annovis Bio Inc	16.23	$ 22.236 Millions	$ 1.370 Millions
Akero Therapeutics Inc	16.17	$ 686.293 Millions	$ 42.439 Millions
Trevi Therapeutics Inc	15.67	$ 103.257 Millions	$ 6.590 Millions
Dianthus Therapeutics Inc	15.53	$ 263.230 Millions	$ 16.953 Millions
Benitec Biopharma Inc	15.51	$ 103.638 Millions	$ 6.680 Millions
Capricor Therapeutics inc	15.25	$ 144.777 Millions	$ 9.495 Millions
Camp4 Therapeutics Corporation	15.24	$ 49.323 Millions	$ 3.236 Millions
Edesa Biotech Inc	15.20	$ 13.900 Millions	$ 0.915 Millions
Lipocine Inc	15.17	$ 19.719 Millions	$ 1.300 Millions
Olema Pharmaceuticals Inc	15.07	$ 392.707 Millions	$ 26.064 Millions
Aprea Therapeutics Inc	15.04	$ 19.276 Millions	$ 1.282 Millions
Regulus Therapeutics Inc	14.87	$ 65.368 Millions	$ 4.397 Millions
Eupraxia Pharmaceuticals Inc	14.52	$ 80.563 Millions	$ 5.550 Millions
Savara Inc	14.50	$ 172.500 Millions	$ 11.898 Millions
Hoth Therapeutics Inc	14.39	$ 11.317 Millions	$ 0.786 Millions
Nuvalent Inc	14.30	$ 1,073.225 Millions	$ 75.034 Millions
Nkarta Inc	14.16	$ 265.507 Millions	$ 18.756 Millions
Rallybio Corporation	13.94	$ 54.495 Millions	$ 3.910 Millions
Climb Bio Inc	13.94	$ 98.062 Millions	$ 7.036 Millions
Bicycle Therapeutics Plc	13.76	$ 792.973 Millions	$ 57.623 Millions
Arrivent Biopharma inc	13.74	$ 176.077 Millions	$ 12.815 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.